Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

Table 4 Comparison of anti-Spike IgG. IgA levels and NAb activity

	Vaccine	Group	Median	P
Anti-Spike IgG level	CoronaVac	IS vs HC (n = 58 vs 142)	234.25 AU/mL vs 457.85 AU/mL	0.002^*
		IS vs INF (n = 58 vs n = 74)	234.25 AU/mL vs 1285 AU/mL	0.000^*
		HC vs INF (n = 142 vs n = 74)	457.85 AU/mL vs 1285 AU/mL	0.000^*
	BNT162b2	IS vs HC (n = 46 vs 121)	5311.20 AU/mL vs 8842.80 AU/mL	0.007^*
		IS vs INF (n = 46 vs 74)	5311.20 AU/mL vs 1285 AU/mL	0.001^*
		HC vs INF (n = 121 vs n = 74)	8842.80 AU/mL vs 1285 AU/mL	0.000^*
Anti-Spike IgA level	CoronaVac	IS vs HC (n = 35 vs n = 16)	0.04 ng/mL vs 0.065 ng /mL	0.218
		IS vs INF (n = 35 vs n = 17)	0.04 ng /mL vs 0.25 ng /mL	0.000^*
		HC vs INF (n = 16 vs n = 17)	0.065 ng /mL vs 0.25 ng /mL	0.017^*
	BNT162b2	IS vs HC (n = 32 vs n = 53)	0.1 ng /mL vs 0.17 ng /mL	0.236
		IS vs INF (n = 32 vs n = 17)	0.1 ng /mL vs 0.25 ng /mL	0.019^*
		HC vs INF (n = 53 vs n = 17)	0.17 ng /mL vs 0.25 ng /mL	0.133
NAb activity	CoronaVac	IS vs HC (n = 37 vs n = 18)	52% vs 60.5%	0.421
		IS vs INF (n = 37 vs n = 17)	52% vs 72%	0.000^*
		HC vs INF (n = 18 vs n = 17)	60.5% vs 72%	0.001^*
	BNT162b2	IS vs HC (n = 35 vs n = 59)	73% vs 90%	0.006^*
		IS vs INF (n = 35 vs n = 17)	73% vs 72%	0.938
		HC vs INF (n = 59 vs n = 17)	90% vs 72%	0.003^*

(IS Immunosuppressive group, HC Healthy controls, INF Infection group, NAb Neutralizing antibody)
(^*p < 0.05)

ISSN: 2520-1026